Business Context and Reporting Period
This Form 8-K is a current report filed by AIT Therapeutics, Inc. on March 22, 2018, regarding events occurring on March 19, 2018. The registrant is a Delaware corporation and an emerging growth company. The filing serves to announce financial results for the quarter and full year ended December 31, 2017.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not detail specific material changes versus prior periods. It solely references the announcement of results for the period ended December 31, 2017, without providing comparative data in the body of the report.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, and unusual items are not detailed in this filing. The report states that the full text of the press release containing this information is furnished as Exhibit 99.1. The filing explicitly notes that the information in this Form 8-K and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (Press Release issued March 19, 2018).
- Confirm the company's status as an emerging growth company and any associated accounting election implications.
- Review the press release for any forward-looking statements or risk factors not included in this summary.
- Note that the financial data in this 8-K is furnished, not filed, and may not be incorporated by reference into other SEC documents.